Which cut-off value of high sensitivity C- reactive protein is more valuable for determining long- term prognosis in patients with acute coronary syndrome?;Akut koroner sendromlu hastalarda yüksek duyarli C-reaktif proteinin uzun dönem prognozu belirlemede hangi kestirim deǧeri daha deǧerlidir?

Anadolu Kardiyoloji Dergisi

Volumn 9, Issue 4, 2009, Pages 280-289

  Kiliç, Teoman ^a   Ural, Ertan ^a   Öner, Gökhan ^a   Şahin, Tayfun ^a   Kiliç, Metehan ^a   Yavuz, Şadan ^a   Kanko, Muhip ^a   Kahraman, Göksel ^a   Bildirici, Ulaş ^a   Berki, Kamil Turan ^a   Ural, Dilek ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

Acute coronary syndrome; High sensitivity C reactive protein; Long term prognosis; Predictive models; Survival analysis

Indexed keywords

C REACTIVE PROTEIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EVENT FREE SURVIVAL; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; THORAX PAIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REFERENCE STANDARDS; REFERENCE VALUES; RISK FACTORS; ROC CURVE;

EID: 70349389760     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: 85-151.
2. White HD, Chew DP. Acute myocardial infarction. Lancet 2008; 372: 570-84.
3. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/ AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary. J Am Coll Cardiol 2004; 44: 671-719.
4. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2007; 28: 1598-660.
5. Anderson JL, Adams CD, Antman EM, Califf RM, Casey DE Jr, Chavey WE 2nd, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2007; 50: e1-e157.
6. Türkiye Kalp Raporu 2000. Tr̈uk Kardiyoloji Derneǧi, Yenilik Basimevi, Istanbul 2000, s. 11-25.
7. Onat A, Keleş I, Aksu H, Çetinkaya A, Yildirim B, Uslu N ve ark. Türk erişkinlerinde toplam ve kardiyak ölümlerin prevalansi: TEKHARF çalişmasinin 8 yillik takip verileri. Türk Kardiyol Dern Arş 1999; 27: 8-14.
8. Corti R, Fuster V, Badimon JJ. Pathogenetic concepts of acute coronary syndromes. J Am Coll Cardiol 2003; 41: 7S-14S.
9. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenisis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-50.
10. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
11. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-26.
12. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
13. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003; 41: 37S-42S.
14. Libby P, Ridker PM. Novel inflammatory markers of coronary risk: theory versus practice. Circulation 1999; 100: 1148-50.
15. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007; 49: 2129-38.
16. Yildirir A. Yeni bir risk faktörü olarak yüksek duyarlikli C-reaktif protein (hsCRP) Türk Kardiyol Dern Arş 2005; 33: 360-71.
17. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959-69.
18. Sabatine MS, Antman EM. The thrombolysis in myocardial infarction risk score in unstable angina/non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2003; 41(4 Suppl S): 89S-95S.
19. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000; 102: 2031-7.
20. Friedewald WT, Levy RI, Fredricksen DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
21. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99: 855-60.
22. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000; 343: 1139-47.
23. Versaci F, Gaspardone A, Tomai F, Crea F, Chiariello L, Gioffrè PA. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. Am J Cardiol 2000; 85: 92-5.
24. Mueller C, Buettner HJ, Hodgson JM, Marsch S, Perruchoud AP, Roskamm H, et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 2002; 105: 1412-5.
25. Zebrack JS, Anderson JL, Maycock CA, Horne BD, Bair TL, Muhlestein JB. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol 2002; 89: 145-9.
26. James SK, Armstrong P, Barnathan E, Califf R, Lindahl B, Siegbahn A, et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol 2003; 41: 916-24.
27. Sanchez PL, Morinigo JL, Pabon P, Martin F, Piedra I, Palacios IF, et al. Prognostic relations between inflammatory markers and mortality in diabetic patients with non-ST elevation acute coronary syndrome. Heart 2004; 90: 264-9.
28. Kiliç T, Ural D, Ural E, Yumuk Z, Aǧaçdiken A, Şahin T, et al. Relation between proinflammatory to anti-inflammatory cytokine ratios and long-term prognosis in patients with non-ST elevation acute coronary syndrome. Heart 2006; 92: 1041-6.
29. Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi M, Mitamura H, et al. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation 1997; 96: 778-84.
30. Tommasi S, Carluccio E, Bentivoglio M, Buccolieri M, Mariotti M, Politano M, et al. C-reactive protein as a marker for cardiac ischemic events in the year after a first, uncomplicated myocardial infarction. Am J Cardiol 1999; 83: 1595-9.
31. Nikfardjam M, Mullner M, Schreiber W, Oschatz E, Exner M, Domanovits H, et al. The association between C-reactive protein on admission and mortality in patients with acute myocardial infarction. J Intern Med 2000; 247: 341-5.
32. Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation. 2006; 114: 281-8.
33. Zairis MN, Adamopoulou EN, Manousakis SJ, Lyras AG, Bibis GP, Ampartzidou OS, et al. The impact of hs C-reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes. Atherosclerosis 2007; 194: 397-402.
34. Scirica BM, Morrow DA, Cannon CP, de Lemos JA, Murphy S, Sabatine MS, et al. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem. 2007; 53: 1800-7.
35. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem 2007; 53: 552-74.
36. Yip HK, Wu CJ, Chang HW, Yang CH, Yeh KH, Chua S, et al. Levels and values of serum high-sensitivity C-reactive protein within 6 hours after the onset of acute myocardial infarction. Chest 2004; 126: 1417-22.
37. Tomoda, H, Aoki, N Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. Am Heart J 2000; 140: 324-8.
38. Rebuzzi AG, Quaranta G, Liuzzo G, Caligiuri G, Lanza GA, Gallimore JR, et al. Incremental prognostic value of serum levels of troponin T and C- reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol 1998; 82: 715-9.
39. Bogaty P, Boyer L, Simard S, Dauwe F, Dupuis R, Verret B, et al. Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (recurrence and inflammation in the acute coronary syndromes) study. J Am Coll Cardiol 2008; 51: 2339-46.
40. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
41. Chew DP, Bhatt DL, Robbins MA, Mukherjee D, Roffi M, Schneider JP, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 2001; 88: 672-4.
42. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. N Engl J Med. 2005; 352: 29-38.
43. Masoudi FA, Plomondon ME, Magid DJ, Sales A, Rumsfeld JS. Renal insufficiency and mortality from acute coronary syndromes. Am Heart J 2004; 147: 623-9.
44. Fox KA, Anderson FA Jr, Dabbous OH, Steg PG, López-Sendón J, Van de Werf F, et al. Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE). Heart 2007; 93: 177-82.
45. Fácila L, Núñez J, Bodí V, Sanchís J, Bertomeu-González V, Consuegra L, Pellicer M, et al. Prognostic value of serum creatinine in non-ST-elevation acute coronary syndrome. Rev Esp Cardiol 2006; 59: 209-16.
46. Gibson CM, Pinto DS, Murphy SA, Morrow DA, Hobbach HP, Wiviott SD, et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol 2003; 42: 1535-43.